top of page
LICENSING and IP USE
Our IP for HRT Pharmaceuticals and Additional Indications
Liqui-Patch® Can Deliver API's for Many Substance Groups and Indications
An important developmental direction that Transdermal Delivery Systems will take is “the path of increasing flexibility, controllability, directability and adjustability.
The Future of Transdermal Delivery Medicines and Use
Our Near Term Focus:
Licensing Liqui-Patch® to Established HRT Pharmaceutical Companies
We are evaluating entrance to the Hormone Replacement Therapy (“HRT”) market, estimated at $20.0 B in 2017
Estrogen / progestin market estimated at $10.0 B
Testosterone replacement market estimated at $5.0 B
We plan to move hormonal therapies into our pipeline
Female hormone replacement therapy (HRT) containing estrogens or a
combination of estrogens and progestins
Male hypogonadism containing testosterone therapy
We are also continually reviewing additional opportunities in therapeutic areas and associated APIs
contact us to discuss licensing
Contact Us for Information on Licensing Liqui-Patch®
Technologies
bottom of page